Simultaneous Reduction of Volume and Dose in Clinical Target Volume for Nasopharyngeal Cancer Patients

doi:10.1016/j.ijrobp.2020.09.034

CNU IR > Pharmacy and Science > Dept. of Biotechnology (including master's program) > Periodical Articles > Item 310902800/34502

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34502

Title:	Simultaneous Reduction of Volume and Dose in Clinical Target Volume for Nasopharyngeal Cancer Patients
Authors:	Liu, Wen-Shan Tsai, Kuo-Wang Kang, Bor-Hwang Yang, Ching-Chieh Huang, Wei-Lun Lee, Ching-Chih Hu, Yu-Chang Chang, Kuo-Ping Chen, Hsiu-Min Lin, Yaoh-Shiang
Contributors:	Kaohsiung Vet Gen Hosp, Dept Radiat Oncol Meiho Univ, Dept Nursing Natl Def Med Ctr, Sch Med Kaohsiung Vet Gen Hosp, Dept Med Educ & Res Taipei Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Res Kaohsiung Vet Gen Hosp, Dept Otorhinolaryngol Head & Neck Surg Chi Mei Med Ctr, Dept Radiat Oncol Chia Nan Univ Pharm & Sci, Dept Pharm Kaohsiung Vet Gen Hosp, Ctr Med Informat, Dept Res
Keywords:	INTENSITY-MODULATED RADIOTHERAPY QUALITY-OF-LIFE CARCINOMA PATIENTS RADIATION-THERAPY LATE TOXICITY COMORBIDITY IMPACT SURVIVAL OUTCOMES HEAD
Date:	2021
Issue Date:	2023-11-11 11:59:31 (UTC+8)
Publisher:	ELSEVIER SCIENCE INC
Abstract:	Purpose: To compare the treatment outcome and severe late adverse effects (AEs) between conventional volume and dose (CVD) and simultaneously reduced volume and dose (SRVD) of clinical target volume treatments in patients with nasopharyngeal carcinoma. Methods and Materials: This retrospective cohort study enrolled patients with nonmetastatic stage II to IV nasopharyngeal cancer from a single institute. Survival endpoints and severe (>= grade 3) late AEs and comorbidity were compared between groups. The correlation of severe late AEs, comorbidity, and overall survival (OS) were evaluated using Kaplan-Meier and Cox regression methods. Results: From January 2012 to June 2017, this study enrolled 178 patients, 64 in the CVD group and 114 in the SRVD group. The 2 groups did not differ significantly in patient characteristics except for mean follow-up time (37.6 vs 48.8 months; P = .01). The SRVD group did not significantly differ from the CVD group in local control survival (82.0% vs 78.4%; P = .85), regional control survival (89.9% vs 86.0%; P = .62), or disease-free survival (76.4% vs 66.9%; P = .67). The SRVD group had significantly better OS (93.9% vs 67.0%; P < .001) and salvage survival (79.3% vs 20.7%; P < .01) and a significantly lower ratio of severe lung infection (1 of 113 vs 5 of 59; P = .02). The SRVD group had a significantly lower risk of mortality (hazard ratio [HR], 0.3; P = .03). The factors associated with a significantly higher risk of mortality were N3 (regional lymph node stage status of N3) (HR, 3.0; P = .02); comorbidities of diabetes, coronary artery disease, or chronic kidney disease (grades 2-3) (HR, 3.8; P = .009), and severe lung infection (HR, 6.3; P = .007). Conclusions: Simultaneously reduced volume and dose of clinical target volumes did not impair locoregional control or disease-free survival. The benefits of SRVD treatment may include significant reduction in severe late AEs, particularly lung infection, dysphagia, and xerostomia. However, additional studies with longer patient follow-up are required to confirm these benefits. (C) 2020 Elsevier Inc. All rights reserved.
Relation:	INT J RADIAT ONCOL, v.109, n.2, pp.495-504
Appears in Collections:	[Dept. of Biotechnology (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	197	View/Open

Loading...